Therapy and prevention of prion protein complex infections

Abstract

There are disclosed therapies and preventions of prion protein complex infections. The transcription of the amyloid precursor protein gene and PrP gene and the RNA transcript are the rate-limiting steps and are most susceptible for blockage and control of the process of amyloid protein formation and PrPsc formation. Thus, therapies and prevention regimes for prion protein complex infections interrupt this process at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons.

1 . A method of treating an individual having a prion protein complex infection which is Alzheimer's disease or preventing an individual from having a prion protein complex infection which is Alzheimer's disease, the infection characterized by amyloid beta pathology and PrP sc  fusion protein pathology, comprising:
 administering to the individual an effective amount of a medication comprising an antibiotic which is minocycline, wherein the medication interrupts transcription of a gene for amyloid precursor protein and RNA transcript at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons; and   administering to the individual an effective amount of an immunosuppressant which is sirolimus, wherein the immunosuppressant impairs the humoral immune system from synthesizing humoral antibodies, amyloid beta and PrP sc  proteins.   
     
     
         2 - 8 . (canceled) 
     
     
         9 . The method of  claim 1  wherein administering sirolimus comprises 2 mg of sirolimus once per day. 
     
     
         10 . The method of  claim 1  wherein the antibiotic and the immunosuppressant are administered together as a unit dose. 
     
     
         11 . (canceled) 
     
     
         12 . The method of  claim 1  wherein administering an effective amount of the antibiotic and administering an effective amount of the immunosuppressant comprises administering the antibiotic and the immunosuppressant for at least three months. 
     
     
         13 . A method of reducing amyloid beta protein and PrP sc  fusion protein complex in a patient with Alzheimer's disease comprising:
 administering to the patient an effective amount of an antibiotic, wherein the antibiotic comprises a tetracycline which is minocycline, wherein the antibiotic interrupts transcription of a gene for amyloid precursor protein and PrP sc  fusion protein complex and the RNA transcript at the level of DNA transcription to RNA, RNA transport to the mitochondrion for protein synthesis and deposition in the cerebral cortex neurons;   administering to the patient an effective amount of an immunosuppressant which is sirolimus, wherein the immunosuppressant impairs the humoral immune system from synthesizing humoral antibodies, amyloid beta and PrPsc proteins.   
     
     
         14 - 15 . (canceled) 
     
     
         16 . The method of  claim 13  wherein administering the antibiotic comprises 50 mg twice per day. 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 13  wherein administering the antibiotic comprises 100 mg of minocycline once per day. 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . The method of  claim 13  wherein administering the immunosuppres sant comprises 2 mg of sirolimus once per day. 
     
     
         22 . The method of  claim 13  wherein the tetracycline and the immunosuppressant are administered together as a unit dose. 
     
     
         23 . (canceled) 
     
     
         24 . The method of  claim 13  wherein administering an effective amount of the antibiotic and administering an effective amount of the immunosuppressant comprises administering the antibiotic and the immunosuppressant for at least three months. 
     
     
         25 . (canceled) 
     
     
         26 . A method of treating an individual having a prion protein complex infection which is Alzheimer's disease or preventing an individual from having a prion protein complex infection which is Alzheimer's disease, consisting essentially of:
 administering to the individual an antibiotic or a pharmaceutically acceptable salt thereof, wherein the antibiotic comprises a minocycline;   an immunosuppressive or a pharmaceutically acceptable salt thereof, wherein the immunosuppressive comprises sirolimus; and   one or more pharmaceutically acceptable carriers, diluents, or excipients.   
     
     
         27 . The method of  claim 26  wherein the minocycline is administered in a dose of 50 mg-100 mg. 
     
     
         28 . (canceled) 
     
     
         29 . The method of  claim 26  wherein sirolimus is administered in a dose of 0.5 mg-2 mg. 
     
     
         30 . The method of clam  26  wherein administration of the minocycline and the sirolimus occurs at least twice per day.